×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
CADL – candel therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
CADL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/11
08:10 am
cadl
Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
Low
Report
Candel Therapeutics, Inc. (NASDAQ: CADL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.
4/1
08:25 am
cadl
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients [Yahoo! Finance]
Medium
Report
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients [Yahoo! Finance]
4/1
08:01 am
cadl
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
Low
Report
Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients
3/26
08:13 pm
cadl
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment [Yaho
Medium
Report
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment [Yaho
3/26
04:05 pm
cadl
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
Medium
Report
Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment
3/26
08:13 am
cadl
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now [Yahoo! Finance]
Medium
Report
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now [Yahoo! Finance]
3/20
08:00 am
cadl
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
Medium
Report
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
3/18
08:00 am
cadl
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
Medium
Report
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D., to Research Advisory Board
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/27
06:01 am
cadl
Form 8-K Candel Therapeutics, For: Mar 26
High
Report
Form 8-K Candel Therapeutics, For: Mar 26
3/20
04:36 pm
cadl
Form 4 Candel Therapeutics, For: Mar 18 Filed by: Nichols William Garrett
Low
Report
Form 4 Candel Therapeutics, For: Mar 18 Filed by: Nichols William Garrett
3/20
04:36 pm
cadl
Form 4 Candel Therapeutics, For: Mar 18 Filed by: Barone Francesca
Low
Report
Form 4 Candel Therapeutics, For: Mar 18 Filed by: Barone Francesca
3/20
04:36 pm
cadl
Form 4 Candel Therapeutics, For: Mar 18 Filed by: Tak Paul Peter
Low
Report
Form 4 Candel Therapeutics, For: Mar 18 Filed by: Tak Paul Peter
3/20
04:35 pm
cadl
Form 4/A Candel Therapeutics, For: Mar 17 Filed by: Tyagarajan Seshu
Low
Report
Form 4/A Candel Therapeutics, For: Mar 17 Filed by: Tyagarajan Seshu
3/19
04:12 pm
cadl
Form 4 Candel Therapeutics, For: Mar 17 Filed by: Tyagarajan Seshu
Medium
Report
Form 4 Candel Therapeutics, For: Mar 17 Filed by: Tyagarajan Seshu
3/19
04:07 pm
cadl
Form 4 Candel Therapeutics, For: Mar 17 Filed by: Schoch Charles
Medium
Report
Form 4 Candel Therapeutics, For: Mar 17 Filed by: Schoch Charles
3/18
04:30 pm
cadl
Form 144 Candel Therapeutics, Filed by: Barone Francesca
Low
Report
Form 144 Candel Therapeutics, Filed by: Barone Francesca
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: